VNDA probrably spent near $200m over the last XX years developing it and waiting all this time sicne the trials ended for approval. It doesnt seem like its a great deal for VNDA - why wouldnt they publish the revenue share?
VNDA - Vanda only has one other drug in its pipeline. I don't know why they didn't just sell themselves for say 500 million which would have been close to a 60% premium. Instead they sign a deal for $465 million. I think investors may have been happier with the former choice.
As an NVS shareholder I certainly agree on the first point (screw up). Whether they have shown wisdom by regaining the rights remains to be seen. I think a re-evaluation of the go, no go decision process is required.
Market Data 
Markets 
AI
